Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$15.13 +1.16 (+8.30%)
As of 02:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$13.99
$15.25
50-Day Range
$8.93
$14.34
52-Week Range
$5.14
$29.46
Volume
509,415 shs
Average Volume
338,678 shs
Market Capitalization
$813.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 735th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Upstream Bio has received no research coverage in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

  • Price to Book Value per Share Ratio

    Upstream Bio has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Upstream Bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for UPB.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UPB.
  • News Sentiment

    Upstream Bio has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for UPB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Upstream Bio begins phase 2 COPD trial for verekitug
UPB Upstream Bio, Inc. - Seeking Alpha
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB shares have decreased by 9.5% and is now trading at $14.8780.

Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The company earned $0.57 million during the quarter, compared to analysts' expectations of $0.71 million.

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Top institutional shareholders of Upstream Bio include CWM LLC (0.01%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/06/2025
Today
7/30/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
CIK
2022626
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$38.00
Potential Upside/Downside
+279.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
47.43
Quick Ratio
47.43

Sales & Book Value

Annual Sales
$2.30 million
Price / Sales
348.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.77 per share
Price / Book
1.70

Miscellaneous

Outstanding Shares
53,794,000
Free Float
46,500,000
Market Cap
$800.35 million
Optionable
N/A
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners